• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

    6/11/25 4:05:00 PM ET
    $BCAX
    $RLAY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BCAX alert in real time by email

    CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025.

    "It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare to initiate our Phase 3 ReDiscover-2 trial in breast cancer soon," said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics.

    Dr. Mazumdar is the founding Chief Executive Officer of Bicara Therapeutics (NASDAQ:BCAX), a clinical-stage oncology company. Prior to Bicara, Dr. Mazumdar led business development and corporate strategy at Rheos Medicines, where she supported the precision medicine company's global partnership with Roche Pharmaceuticals. Earlier in her career, she held a position at Third Rock Ventures, where she focused on company formation and business development. She holds a B.S. in biological engineering from the Massachusetts Institute of Technology and earned both an MBA from Stanford Graduate School of Business and a Ph.D. in cancer biology from Stanford School of Medicine.

    About Relay Therapeutics

    Relay Therapeutics (NASDAQ:RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what's possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics' initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Relay Therapeutics' strategy, business plans and focus; the progress and timing of the clinical development of the programs across Relay Therapeutics' portfolio; the expected therapeutic benefits and potential efficacy and tolerability of RLY-2608, both as a monotherapy and in combination with other agents, and its other programs, as well as the clinical data for RLY-2608; the interactions with regulatory authorities and any related approvals; the potential market opportunity for RLY-2608; the cash runway projection; the expected benefits resulting from the implementation of the cost saving measures and potential ability to fund key value drivers; and the expectations regarding Relay Therapeutics' use of capital and expenses. The words "may," "might," "will," "could," "would," "should," "plan," "anticipate," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

    Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: Relay Therapeutics' restructuring activities may be more costly or time-consuming than we expect or may not achieve their intended results; the timing, execution, and expected impact of Relay Therapeutics' restructuring plans (including the scope and timing of workforce reductions); the expected decrease in annual spending; the expected sufficiency of Relay Therapeutics' existing cash resources; the internal and external costs required for Relay Therapeutics' ongoing and planned activities, and the resulting impact on expense and use of cash, may be higher than expected, which may cause the company to use cash more quickly than expected or to change or curtail some of Relay Therapeutics' plans or both; the impact of global economic uncertainty, geopolitical instability and conflicts, or public health epidemics or outbreaks of an infectious disease on countries or regions in which Relay Therapeutics has operations or does business, as well as on the timing and anticipated results of its clinical trials, strategy, future operations and profitability; significant political, trade, or regulatory developments, such as tariffs, beyond Relay Therapeutics' control; the delay or pause of any current or planned clinical trials or the development of Relay Therapeutics' drug candidates; the risk that the preliminary or interim results of its preclinical or clinical trials may not be predictive of future or final results in connection with future clinical trials of its product candidates and that interim and early clinical data may change as more patient data become available and are subject to audit and verification procedures; Relay Therapeutics' ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of its planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Relay Therapeutics' most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Relay Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. Relay Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

    Contact:

    Pete Rahmer

    [email protected]

    Media:

    Dan Budwick

    1AB

    973-271-6085

    [email protected]  



    Primary Logo

    Get the next $BCAX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BCAX
    $RLAY

    CompanyDatePrice TargetRatingAnalyst
    Bicara Therapeutics Inc.
    $BCAX
    5/23/2025$8.00Underweight → Equal Weight
    Wells Fargo
    Relay Therapeutics Inc.
    $RLAY
    4/17/2025$4.00Equal Weight
    Wells Fargo
    Bicara Therapeutics Inc.
    $BCAX
    4/17/2025$8.00Underweight
    Wells Fargo
    Bicara Therapeutics Inc.
    $BCAX
    2/6/2025$31.00Outperform
    Wedbush
    Bicara Therapeutics Inc.
    $BCAX
    12/6/2024$42.00Buy
    H.C. Wainwright
    Bicara Therapeutics Inc.
    $BCAX
    11/5/2024$48.00Buy
    Rodman & Renshaw
    Bicara Therapeutics Inc.
    $BCAX
    10/8/2024Overweight
    Cantor Fitzgerald
    Bicara Therapeutics Inc.
    $BCAX
    10/8/2024$35.00Overweight
    Morgan Stanley
    More analyst ratings

    $BCAX
    $RLAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Possible Members of 10% Group Flynn James E converted options into 1,725,174 shares and bought $1,260,000 worth of shares (70,000 units at $18.00) (SEC Form 4)

      4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

      9/17/24 6:16:55 PM ET
      $BCAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCAX
    $RLAY
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Bicara Therapeutics Inc.

      SCHEDULE 13G - Bicara Therapeutics Inc. (0002023658) (Subject)

      7/17/25 11:11:22 AM ET
      $BCAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Bicara Therapeutics Inc.

      SCHEDULE 13G/A - Bicara Therapeutics Inc. (0002023658) (Subject)

      7/17/25 11:08:54 AM ET
      $BCAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Bicara Therapeutics Inc.

      144 - Bicara Therapeutics Inc. (0002023658) (Subject)

      6/16/25 4:29:21 PM ET
      $BCAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCAX
    $RLAY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Omega Funds Closes Oversubscribed $647 Million Fund VIII to Invest in Transformative Life Science Companies

      Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs. Since its inception in 2004, Omega Funds has raised $2.5 billion to invest in exceptional entrepreneurs developing

      7/21/25 7:00:00 AM ET
      $BBNX
      $BCAX
      $KMTS
      $MORF
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 20, 2025 /PRNewswire/ -- USA News Group News Commentary – The costs of cancer drugs is skyrocketing, according to a recent report from Bloomberg. Analysts at Nova One Advisor estimate that the global oncology drugs market will grow at a 7.4% CAGR through to US$366.24 billion by 2034. Help doesn't appear to be coming from the public sector, as reports state that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment.

      6/20/25 9:21:00 AM ET
      $GRAL
      $IMRX
      $INTS
      $ONCY
      Medical Specialities
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

      CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025. "It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare to initiate our Phase 3 ReDiscover-2 trial in breast cancer soon," said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics.

      6/11/25 4:05:00 PM ET
      $BCAX
      $RLAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $BCAX
    $RLAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Patel Sanjiv sold $219,123 worth of shares (61,379 units at $3.57), decreasing direct ownership by 7% to 765,288 units (SEC Form 4)

      4 - Relay Therapeutics, Inc. (0001812364) (Issuer)

      7/10/25 4:55:22 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Rahmer Peter was granted 5,000 shares, increasing direct ownership by 1% to 395,081 units (SEC Form 4)

      4 - Relay Therapeutics, Inc. (0001812364) (Issuer)

      7/1/25 5:00:16 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Patel Sanjiv was granted 5,000 shares, increasing direct ownership by 0.61% to 826,667 units (SEC Form 4)

      4 - Relay Therapeutics, Inc. (0001812364) (Issuer)

      7/1/25 4:59:29 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAX
    $RLAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bicara Therapeutics upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Bicara Therapeutics from Underweight to Equal Weight and set a new price target of $8.00

      5/23/25 12:55:35 PM ET
      $BCAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Relay Therapeutics with a new price target

      Wells Fargo initiated coverage of Relay Therapeutics with a rating of Equal Weight and set a new price target of $4.00

      4/17/25 8:33:19 AM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wells Fargo initiated coverage on Bicara Therapeutics with a new price target

      Wells Fargo initiated coverage of Bicara Therapeutics with a rating of Underweight and set a new price target of $8.00

      4/17/25 8:32:06 AM ET
      $BCAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCAX
    $RLAY
    Leadership Updates

    Live Leadership Updates

    See more
    • Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

      CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025. "It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare to initiate our Phase 3 ReDiscover-2 trial in breast cancer soon," said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics.

      6/11/25 4:05:00 PM ET
      $BCAX
      $RLAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Section 32 Raises $740 Million Venture Fund

      SAN DIEGO, Nov. 4, 2021 /PRNewswire/ -- Section 32 announced today the closing of its fourth fund, raising approximately $740 million from returning and new investors. Investors in Fund 4 include leading philanthropic and non-profit organizations, educational endowments and foundations, and leaders from the technology and healthcare sectors. Section 32 Fund 4 will support companies across all stages that are pioneering innovations at the forefront of technology and healthcare. With the closing of its oversubscribed Fund 4 and to support its continued growth, Section 32 also announced the appointment of Nina Labatt to the role of Chief Operating Officer and Chief Financial Officer.

      11/4/21 8:14:00 AM ET
      $COIN
      $CRWD
      $EXAS
      $RLAY
      Finance: Consumer Services
      Finance
      Computer Software: Prepackaged Software
      Technology
    • Octant Bio Appoints Industry Veteran Mark Murcko as Strategic Advisor and Board Member

      Murcko brings over 30 years of chemistry development in biotech experience to the synthetic biology startup Today, Octant, a therapeutics company integrating novel high-throughput experimental technologies with computation to solve complex challenges in drug discovery, announced the appointment of Mark Murcko as Strategic Advisor and Board Member. Murcko brings over three decades of industry experience, having been at the center of many transformational biotech efforts, most recently as founding CSO and Board Member of Dewpoint Therapeutics. Murcko is working closely with the company to scale Octant to its next phase of growth and further develop its chemistry platform. This press release

      10/14/21 8:00:00 AM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAX
    $RLAY
    Financials

    Live finance-specific insights

    See more
    • Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

      Median DOR of 21.7 months with 80% of responders achieving a deep response (≥80% tumor shrinkage) Depth and durability translating to prolonged OS with median OS of 21.3 months and 2-year OS of 46% in HPV-negative HNSCC Conference call and webcast today at 3:00 p.m. CT / 4:00 p.m. ET BOSTON, June 01, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today presented updated data from the company's Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab in patients with first line (1L) recurrent/metastatic (R/M) head an

      6/1/25 1:12:00 PM ET
      $BCAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting

      BOSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the publication of an abstract with updated interim data from the company's Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab in patients with first line (1L) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) on the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting website. The company will host a conference call on Sunday, June 1, 2025 at 3:00 p.m. CT / 4:00 p.m. ET to present the fulsome dataset

      5/22/25 5:00:00 PM ET
      $BCAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival

      New interim data show 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed ORR across all patients & 67% in patients with kinase mutations at RP2D Data support planned initiation of 2L pivotal study in 2025 Next-generation triplet combination with atirmociclib (CDK4-selective) initiated & ribociclib triplet combination ongoing Relay Therapeutics to host a conference call today, December 11, at 7am ET (6am CT) SAN ANTONIO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and expe

      12/11/24 6:00:00 AM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAX
    $RLAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Relay Therapeutics Inc.

      SC 13G/A - Relay Therapeutics, Inc. (0001812364) (Subject)

      11/14/24 1:22:38 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Bicara Therapeutics Inc.

      SC 13G - Bicara Therapeutics Inc. (0002023658) (Subject)

      9/26/24 4:30:56 PM ET
      $BCAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Bicara Therapeutics Inc.

      SC 13G - Bicara Therapeutics Inc. (0002023658) (Subject)

      9/26/24 4:16:04 PM ET
      $BCAX
      Biotechnology: Pharmaceutical Preparations
      Health Care